EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study

Junko Tanaka iD, Akemi Kurisu, Ko Ko iD, Aya Sugiyama, Tomoyuki Akita iD

Hepatology Research · 2026-08 · 56 (8) · 1213-1224

DOI: 10.1111/hepr.70174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 28.03.2026. Verfasst von Junko Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hiroshima University, Hiroshima, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MHLW Policy Research for Hepatitis Measures Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver‐related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long‐term projections are limited. We aimed to estimate the number of carriers and patients in Japan in 2020 and to project through 2050.

Methods

The carriers were classified into six categories: undiagnosed carriers, patients in care, diagnosed but not linked to care, new infections, cured, and deceased. Multiple nationwide data sources—including the National Database of Health Insurance Claims (NDB), public statistics, clinical information, and large‐scale blood donor screening data—were integrated to estimate the size of each category. The Markov model incorporating treatment status and liver disease progression was used to simulate annual changes from 2021 to 2050.

Results

In 2020, the total estimated number of carriers and patients was 1,104,406–1,424,420 (532,159–618,684, aged ≤ 69 years), including HBV: 923,893–940,647 (454,167–461,408, ≤ 69 years) and HCV: 180,513–483,773 (77,992–157,276, ≤ 69 years). Diagnosis and treatment rates exceeded WHO 2030 targets for HBV (95% and 83%–84%; 94% and 99%–100%, ≤ 69 years) and approached targets for HCV (82%–93% and 78%–100%; 75%–88% and 98%–100%, ≤ 69 years). Under current conditions, HCV infections are projected to decline to < 20,000 by 2050, whereas HBV will decrease more gradually to 200,000.

Conclusions

The chronic HBV and HCV burden in Japan declined markedly, particularly for HCV, reflecting progress in prevention, diagnosis, and treatment and offering a model for hepatitis elimination.

Schlagwörter

Stichwörter der Autor:innen

Markov modelhepatitis Bhepatitis Cmass screeningnational database (NDB)

Autor:innen und Institutionen

  • Hiroshima University, Hiroshima, Japan.
  • Department of Epidemiology, Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

ORCID-Profile: Junko Tanaka, Ko Ko, Tomoyuki Akita

Förderung

  • MHLW Policy Research for Hepatitis Measures Program

Zitieren

APA

Tanaka, J., Kurisu, A., Ko, K., Sugiyama, A., & Akita, T. (2026). Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study. Hepatology Research, 56(8), 1213-1224. https://doi.org/10.1111/hepr.70174

Vancouver

Tanaka J, Kurisu A, Ko K, Sugiyama A, Akita T. Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study. Hepatology Research. 2026;56(8):1213-1224. doi:10.1111/hepr.70174

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Junko and Kurisu, Akemi and Ko, Ko and Sugiyama, Aya and Akita, Tomoyuki},
  title = {Updated Burden and Long‐Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {1213--1224},
  doi = {10.1111/hepr.70174}
}
Kostenlos starten →